Trial
NCT01876953
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Intervention
cytarabine
Why stopped
Due to the budget issues, the study discontinued at Phase II.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-31